Effect of carvedilol on survival in severe chronic heart failure

New England Journal of Medicine

Volumn 344, Issue 22, 2001, Pages 1651-1658

  Packer, Milton ^a   Coats, Andrew J S ^b   Fowler, Michael B ^c   Katus, Hugo A ^d   Krum, Henry ^e   Mohacsi, Paul ^f   Rouleau, Jean L ^j   Tendera, Michal ^g   Castaigne, Alain ^h   Roecker, Ellen B ⁱ   Schultz, Melissa K ⁱ   DeMets, David L ⁱ  

^a Columbia University ^*  (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF BERN   (Switzerland)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

^j Columbia Univ Coll Phys Surgs ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; METOPROLOL; PLACEBO; SODIUM ION; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0035978763     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105313442201     Document Type: Article

References (32)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283: 1295-302.
5. Domanski MJ. Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2000;35:Suppl A:202A-203A. abstract.
6. Lechat P, Bouzamondo A, Sanchez P, Hulot JS, Eichhorn EJ, Cucherat M. Relationships between baseline risk and treatment effect of beta-blockers in heart failure. Eur Heart J 2000;21:Suppl:297. abstract.
7. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
8. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation 1995;92:Suppl I:I-395. abstract.
9. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:Suppl 1:39-52.
10. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000;101:122-4.
11. Qin F, Shite J, Liand C-S. Reduction of oxidative stress by trolox and superoxide dismutase abolishes norepinephrine-induced myocyte apoptosis and β-adrenergic receptor downregulation in ferrets. J Am Coll Cardiol 2000;35:Suppl A:168A-169A. abstract.
12. Ohlstein EH, Arleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 1998;30;167-73.
13. B receptor antagonist. Circulation 1996;93:2068-79.
14. Suzuki M, Ohte N, Wang ZM, Williams DL Jr, Little WC, Cheng CP. Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Cardiovasc Res 1998;39:589-99.
15. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
16. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-202.
19. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
21. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
22. Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am J Cardiol 2000;86:886-9.
23. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
25. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963;34:320-4.
26. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6. [Erratum, Lancet 1990;336:698.]
27. Weyl JD, Snyder RW, Hanson RC. Differential cardioprotective properties of the 1- and d- enantiomers of bucindolol in a canine model of heart failure. Arch Int Pharmacodyn Ther 1985;275:4-12.
28. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999;289:48-53.
29. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-67.
30. 1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol 1998;275:H1338-H1350.
31. Downing SE, Lee JC. Contribution of α-adrenoceptor activation to the pathogencsis of norcpinephrine cardiomyopathy. Circ Res 1983;52:471-8.
32. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.